Trial Profile
A Registry to describe clinical experience with Thymoglobuline used as induction immunosuppression in patients undergoing renal transplantation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 13 Dec 2017 New trial record